Results 181 to 190 of about 25,216 (236)

Amivantamab Monotherapy for Lung Adenocarcinoma With Leptomeningeal Seeding: A Case Report

Respirology Case Reports, Volume 14, Issue 3, March 2026.
We report a case of a patient with NSCLC who developed leptomeningeal seeding (LMS) after failure of first‐line therapy and showed a marked clinical and radiologic response to amivantamab monotherapy. ABSTRACT Non–small cell lung cancer (NSCLC) is characterised by a number of driver mutations, among which epidermal growth factor receptor (EGFR) exon 20
Kyeoungseo Park, So Yeon Kim, Sang‐Won Um   +2 more
wiley   +1 more source

Bispecific antibody for lung cancer: mechanisms and clinical insights. [PDF]

Front Immunol
Chen W, Zhou A, Zhou Y.
europepmc   +1 more source

T‐Cell Immunity and Lung Cancer

Respirology, Volume 31, Issue 3, Page 236-249, March 2026.
ABSTRACT Lung cancer remains a leading cause of cancer mortality worldwide. Although immune checkpoint inhibitors (ICIs) have reshaped therapeutic strategies in lung cancer, their benefits remain limited. ICIs exert their therapeutic efficacy by activating T‐cell effector functions, underscoring the central role of T cells in antitumor immunity.
Kotaro Yamada, Yosuke Togashi
wiley   +1 more source

Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma. [PDF]

Haematologica
Siegel A, Reci S, Grossman L, Gleason C, Crary J, Song L, Park J, Verina D, Desai S, Kappes K, Stillman I, LaBaer J, Aleman A, Jagannath S, Parekh S.   +14 more
europepmc   +1 more source

Advances in Engineered Extracellular Vesicles for the Treatment of Atherosclerosis and Atherothrombosis – Next‐Generation Cardiovascular Nanomedicine

Small Structures, Volume 7, Issue 3, March 2026.
Exosomes (small extracellular vesicles) are nanosized vesicles produced naturally by living cells. They can be engineered by various techniques to deliver biologically active molecules to injury sites in atherosclerosis and atherothrombosis. Therefore, an exosome‐based multifunctional nanomedicine for the diagnosis, monitoring, and treatment of these ...
Tuan Huu Nguyen, Nhu Thao Huynh, Be'eri Niego, Christoph E. Hagemeyer, Rong Xu   +4 more
wiley   +1 more source

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Myeloid‐derived suppressor cells (MDSCs) are key contributors to cancer immunotherapy failure and major targets in new therapeutic strategies. We highlight therapeutic approaches to counteract their immunosuppressive functions and discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod as a representative drug ...
Yanying He, Yoon Yeo
wiley   +1 more source

Design and development of a bispecific antibody targeting BAFF and IL-17 for systemic lupus erythematosus treatment. [PDF]

BMC Biol
Xin C, Zhou J, Chen Y, Liu Y, Liu H, Liang C, Zhu X, Qi Y, Zhang G, Wang A.   +9 more
europepmc   +1 more source

Tumour progression shows decrease in PD‐L1 expression in matched metastases/primary uveal melanomas

Acta Ophthalmologica, Volume 104, Issue 2, Page 164-172, March 2026.
Abstract Purpose Immune checkpoint inhibitors (ICI) have revolutionised the treatment of several malignancies. However, the results of ICI therapy remain unsatisfactory in metastatic uveal melanoma (UM). We analysed the expression of PD1, PD‐L1, T‐cell and macrophage markers in a set of matched primary and metastatic UM in an attempt to better ...
Maria Chiara Gelmi, Gulçin Gezgin, Ellen Kapiteijn, T. H. Khanh Vu, Martine J. Jager, Robert M. Verdijk   +5 more
wiley   +1 more source

Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort. [PDF]

Br J Haematol
Noveihed A, Al Hadidi S, Mohan M, Shah MR.   +3 more
europepmc   +1 more source

A Transcriptomic Analysis of Cancer‐Stromal Interactome in Lung Cancer Xenograft Models

Cancer Science, Volume 117, Issue 3, Page 841-851, March 2026.
We conducted a comprehensive analysis of the lung cancer interactome to identify key ligand–receptor pairs involved in the aggressiveness of lung adenocarcinoma. Tumor necrosis factor superfamily member 12 and its receptor tumor necrosis factor receptor superfamily member 12A signaling axis may be potential candidates for therapeutic intervention for ...
Yuriko Takayama‐Isagawa, Daisuke Komura, Takayuki Isagawa, Yusuke Amano, Atsushi Kihara, Tamaki Miura, Taichiro Yoshimoto, Hiroyoshi Tsubochi, Kazutaka Fujita, Koichi Hagiwara, Makoto Maemondo, Tetsuo Ushiku, Shumpei Ishikawa, Noriyoshi Fukushima, Kentaro Inamura, Daisuke Matsubara, Toshiro Niki   +16 more
wiley   +1 more source